Immutep (NASDAQ: IMMP)
FY 2021 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-09-23 | ||||||
REV |
H1 2021 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.020 | ||||||
REV | 2.852M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Immutep (NASDAQ: IMMP) through any online brokerage.
Other companies in Immutep’s space includes: Graphite Bio (NASDAQ:GRPH), Jounce Therapeutics (NASDAQ:JNCE), Inozyme Pharma (NASDAQ:INZY), MoonLake (NASDAQ:MLTX) and Gritstone Bio (NASDAQ:GRTS).
The latest price target for Immutep (NASDAQ: IMMP) was reported by Ladenburg Thalmann on Tuesday, August 3, 2021. The analyst firm set a price target for 8.30 expecting IMMP to rise to within 12 months (a possible 293.36% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Immutep (NASDAQ: IMMP) is $2.11 last updated July 6, 2022, 8:00 PM UTC.
There are no upcoming dividends for Immutep.
Immutep’s FY earnings are confirmed for Friday, September 23, 2022.
There is no upcoming split for Immutep.
Immutep is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.